Here's a new summary of all the drugs in the pipeline currently being evaluated for the treatments of vasculitis.

Molecular-guided decision-making improves disease control and remission in the treatment of IBD with anti-TNF therapy, however, application to other therapies is questioned.

Immunosuppressants represent a second-line treatment option for refractory moderate-to-severe ulcerative colitis, particularly for patients who are either unresponsive to glucocorticoids or dependent ...

Respondr TNF is the first test to predict an inflammatory bowel disease (IBD) patient's likelihood to respond to infliximab, adalimumab and their biosimilars prior to therapy administration.

Six abstracts accepted for presentation includes post hoc analyses and real-world evidence for ZYMFENTRA ® (infliximab-dyyb) Findings reinforce clinical decision-making in long-term management ...

One review of studies showed that drugs that block two specific proteins -- interleukin-17 and interleukin-23 -- cleared skin better than ones that inhibit a protein called TNF-alpha. Your doctor ...

Our results indicate that there is a connection between the administration of TNF-α blockers in the population and the adverse events of thrombosis, which is in line with previous research results.

Since Humira hit the market, other TNF inhibitors have also been approved including Johnson & Johnson’s Remicade (infliximab), Amgen’s Enbrel (etanercept) and UCB’s Cimzia (certolizumab pegol). Give ...

Forbes contributors publish independent expert analyses and insights. News and opinion about video games, television, movies and the internet.